Vergleich Gastrinrezeptorszintigraphie mit 111-In-DTPA-D-Glu1-Minigastrin versus Somatostatinrezeptorszintigraphie mit 111-In-DTPA-D-Phe1-Octreotid bei Patienten mit neuroendokrinen Tumoren.

60 Patienten mit neuroendokrinen Tumoren erhielten sowohl eine Somatostatinrezeptorszintigraphie (SRS) als auch eine Gastrinrezeptorszintigraphie mit (GRS) (51 Karzinoide, 3 Gastrinome, 2 Glukagonome, 1 Insulinom, 3 Paragangliome). Die SRS deckte bei 81,7% der Patienten Tumorl�sionen auf, die GRS i...

Full description

Saved in:
Bibliographic Details
Main Author: Graß, Julia
Contributors: Behr, T.M. (Prof. Dr.) (Thesis advisor)
Format: Doctoral Thesis
Published: Philipps-Universität Marburg 2006
Online Access:PDF Full Text
Tags: Add Tag
No Tags, Be the first to tag this record!
Table of Contents: 60 patients with neuroendocrine tumors received a somatostatin receptor szintigraphy (SRS) and a gastrin receptor scintigraphy (GRS) (51 carcinoids, 3 gastrinomas, 2 glucagonomas, 1 insulinoma, 3 paragangliomas). In 81.7% of the patients, SRS detected tumor lesions. In GRS, 78.3% were positive. In 68.3%, both techniques showed positive results. GRS was positive in 54.5% of SRS negative patients. Overall, GRS showed a better performance than SRS in 21.7% while SRS was better in 40.0%. Conclusion: Though overall performance of SRS may be better, GRS should be performed in patients with gastrointestinal neuroendocrine tumors after SRS, when SRS is negative.